Drug Trial Radar · NCT07587099
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,170
Planned (sponsor's estimate)
Start
May 4, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Gan LijunAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in the chronic coronary syndrome (CCS) and stable Acute Coronary Syndrome (S-ACS) patients undergoing percutaneous coronary intervention (PCI) with the latest generation rapamycin drug-coated balloon (DCB) without stent implantation. The study aims to assess rates of ischemic and bleeding adverse events.
Conditions
- Coronary Heart Disease (CHD)
Interventions
Drug-coated balloonDevice
Fireliums rapamycin eluting coronary balloon dilatation catheter is a rapid exchange catheter, it has a patented microcrystalline coating process to ensure rapid drug delivery to the blood vessel wall and achieve a long-lasting sustained release effect, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
Single antiplatelet therapy (SAPT)Drug
The antithrombotic regimen is single antiplatelet (P2Y12 inhibitor)therapy (SAPT). The Investigator will decide whether to use ticagrelor first; if ticagrelor is not the first-line recommended drug, then clopidogrel will be considered. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
Dual antiplatelet therapy (DAPT)Drug
The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Net Adverse Clinical Events (NACE) at 12 months after randomizationTime frame: 12 months after randomization
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Beijing Luhe Hospital Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China · Not yet recruiting
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Heze Municipal Hospital
Heze, Shandong, China · Not yet recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Not yet recruiting
Shandong Provincial Third Hospital
Jinan, Shandong, China · Not yet recruiting
Affiliated Hospital of Jining Medical University
Jining, Shandong, China · Recruiting
Liaocheng People's Hospital
Liaocheng, Shandong, China · Not yet recruiting
Qingdao Municipal Hospital
Qingdao, Shandong, China · Not yet recruiting
Tai'an City Central Hospital
Tai’an, Shandong, China · Not yet recruiting
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, China · Not yet recruiting
Shanghai Fengxian District People's Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.